CARL News & Events

Carlsmed announced the first personalized cervical plating procedure using the corra Cervical Plating System, the latest addition to its portfolio of personalized spine surgery solutions. The company is preparing for the planned commercial launch of the corra system later this year.

Carlsmed announced the successful completion of the first posterior lumbar spine surgery using the Company's aprevo Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado. "This clinical milestone strengthens our position as a leader in personalized, data-driven spine solutions designed to help surgeons plan with greater precision, improve patient outcomes, and reduce costly revisions. The addition of the aprevo(R) Bi-lateral Posterior Lumbar Interbody Fusion procedure to our personalized surgery procedure portfolio further demonstrates the power and versatility of our personalized, AI-enabled approach to spine surgery," said Mike Cordonnier, Chairman and CEO of Carlsmed. "We look forward to our full commercial launch this year to provide this personalized procedural option to patients, surgeons, and hospital systems on a larger scale."

Fourth quarter 2025 revenue was approximately $15.2 million, an approximate 61% increase compared to the fourth quarter 2024. Full year 2025 revenue was approximately $50.5 million, an approximate 86% increase compared to the full year 2024. "Our fourth quarter commercial performance capped a transformational year for Carlsmed and underscores the power of aprevo(R). This platform technology provides surgeons with greater procedural predictability and has the potential to meaningfully improve clinical outcomes in spine fusion and lower the total cost of care for the healthcare system. With growing enthusiasm for aprevo, we added 101 new surgeon users in 2025, representing a 61% increase in our total surgeon user base over the prior year," said Mike Cordonnier, Chairman and CEO. "As we enter 2026, we are focused on executing our strategy for the next phase of growth with operational excellence. We are energized by the momentum in our business and the recent launch of aprevo cervical, with highly encouraging early surgeon feedback for our patient-specific cervical solution. In 2026, we anticipate growing recognition and adoption of aprevo as a platform technology that we believe is capable of transforming surgical standards and patient outcomes in spine fusion."